搜索结果
靶点ID:TCMBANKGE000828
靶点别名:PLOSL2; TREM-2; Trem2a; Trem2b; Trem2c
靶点描述:triggering receptor expressed on myeloid cells 2
染色体:6
染色体位置:6p21.1
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:17761
OMIM_Link:605086
Ensembl_Link:ENSG00000095970
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN061570 | curcumin | (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin | IC21H20O6 | 368.4 g/mol | COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000419 | - | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI002446 | - | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI002606 | Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases | Abnormality of the respiratory system | Sign or Symptom | phenotype | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003580 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI003655 | - | Abnormality of the nervous system | Pathologic Function | phenotype | |
| TCMBANKDI004145 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI004576 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI004646 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI004922 | Nutritional and Metabolic Diseases; Nervous System Diseases; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI005846 | Nervous System Diseases; Mental Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI006127 | Nervous System Diseases; Mental Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI006165 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI006652 | Nutritional and Metabolic Diseases; Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI007964 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms | Abnormality of the nervous system | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI008112 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI010968 | Nervous System Diseases; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI011174 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI012119 | Pathological Conditions, Signs and Symptoms | Abnormality of the nervous system | Cell or Molecular Dysfunction | phenotype | |
| TCMBANKDI012157 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | group | |
| TCMBANKDI012362 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI013541 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI014161 | Stomatognathic Diseases | Abnormality of the immune system; Abnormality of head or neck | Disease or Syndrome | group | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI015932 | - | - | Finding | phenotype | |
| TCMBANKDI016439 | Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI016612 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI017187 | Behavior and Behavior Mechanisms | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI017191 | Nervous System Diseases; Mental Disorders; Behavior and Behavior Mechanisms | Abnormality of the nervous system | Sign or Symptom | phenotype | |
| TCMBANKDI017474 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI017965 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI019227 | - | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI020373 | - | Abnormality of the musculature | Pathologic Function | phenotype | |
| TCMBANKDI020582 | - | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI020794 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI021151 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI022565 | - | - | Finding | phenotype | |
| TCMBANKDI023044 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI023834 | Nervous System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI024795 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI025156 | Behavior and Behavior Mechanisms | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI025368 | Infections; Nervous System Diseases; Mental Disorders | - | Disease or Syndrome | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI025529 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI026823 | Nutritional and Metabolic Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026963 | Pathological Conditions, Signs and Symptoms | - | Acquired Abnormality | disease | |
| TCMBANKDI027406 | - | Abnormality of the nervous system; Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI028799 | Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI029658 | - | Abnormality of the eye | Finding | disease | |
| TCMBANKDI029791 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI030716 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI030929 | Nervous System Diseases; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI031083 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI031461 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI032222 | Nervous System Diseases; Mental Disorders | - | Mental or Behavioral Dysfunction | disease |
滇IICP备16009434号-1 |
Dai SX Lab